IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
Relative valuation derived from Healthcare sector median benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Multiples adjusted for extreme outliers and non-recurring volatility.
Auditing capital efficiency...
Quality Profile Audit
Score: 41.2GRADE C
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation.
Return on Equity
Profit generated per dollar of shareholder equity
-21.4%
Sector: -43.5%
Dividend Analysis audit
No Dividend
This company does not currently pay a dividend.
Analyst Projections
Analyst Consensus
Unlock Valuation Tools
Sign up for free access to institutional-quality research tools.
Based on our 6-factor quantitative model, Pharming Group N.V. (PHAR) receives a "Hold" rating with a composite score of 55.3/100, ranked #522 out of 4446 stocks. Key factor scores: Quality 41/100, Value 45/100, Momentum 78/100. This is quantitative analysis only — not investment advice.
Pharming Group N.V. (PHAR) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does Pharming Group N.V. Do?
Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands. Pharming Group N.V. (PHAR) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Sijmen d. Vries and employs approximately 280 people. With a market capitalization of $1.2B, PHAR is one of the notable companies in the Healthcare sector.
Pharming Group N.V. (PHAR) Stock Rating — Hold (April 2026)
As of April 2026, Pharming Group N.V. receives a Hold rating with a composite score of 55.3/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.PHAR ranks #522 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Pharming Group N.V. ranks #26 of 838 stocks, placing it in the top 10% of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
PHAR Stock Price and 52-Week Range
Pharming Group N.V. (PHAR) currently trades at $16.98. The 52-week high for PHAR is $21.34, which means the stock is currently trading -20.4% from its annual peak. The 52-week low is $7.50, putting the stock 126.3% above its annual trough. Recent trading volume was 0 shares, suggesting relatively thin trading activity.
Is PHAR Overvalued or Undervalued? — Valuation Analysis
Pharming Group N.V. (PHAR) carries a value factor score of 45/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The price-to-book ratio stands at 5.25x, versus the sector average of 2.75x. The price-to-sales ratio is 0.98x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, PHAR trades at 63.70x EV/EBITDA, versus 6.34x for the sector.
Overall, PHAR's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.
Pharming Group N.V. Profitability — ROE, Margins, and Quality Score
Pharming Group N.V. (PHAR) earns a quality factor score of 41/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -21.4%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -11.8% versus the sector average of -33.1%.
On a margin basis, Pharming Group N.V. reports gross margins of 88.1%, compared to 71.5% for the sector. The operating margin is -2.9% (sector: -66.1%). Net profit margin stands at -4.0%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.
PHAR Debt, Balance Sheet, and Financial Health
Pharming Group N.V. has a debt-to-equity ratio of 49.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. Total debt on the balance sheet is $109M. Cash and equivalents stand at $55M.
PHAR has a beta of 0.75, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Pharming Group N.V. is 48/100, reflecting average volatility within the normal range for its sector.
Pharming Group N.V. Revenue and Earnings History — Quarterly Trend
In TTM 2026, Pharming Group N.V. reported revenue of $297M and earnings per share (EPS) of $-0.02. Net income for the quarter was $-12M. Gross margin was 88.1%. Operating income came in at $-9M.
In FY 2024, Pharming Group N.V. reported revenue of $297M and earnings per share (EPS) of $-0.02. Net income for the quarter was $-12M. Gross margin was 88.1%. Revenue grew 138.4% year-over-year compared to FY 2023. Operating income came in at $-9M.
In FY 2023, Pharming Group N.V. reported revenue of $125M and earnings per share (EPS) of $-0.02. Net income for the quarter was $-11M. Gross margin was 176.6%. Revenue grew -39.4% year-over-year compared to FY 2022. Operating income came in at $-25M.
In FY 2022, Pharming Group N.V. reported revenue of $206M and earnings per share (EPS) of $0.02. Net income for the quarter was $14M. Gross margin was 91.5%. Revenue grew 3.4% year-over-year compared to FY 2021. Operating income came in at $18M.
Over the past 7 quarters, Pharming Group N.V. has demonstrated a growth trajectory, with revenue expanding from $190M to $297M. Investors analyzing PHAR stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
PHAR Dividend Yield and Income Analysis
Pharming Group N.V. (PHAR) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
PHAR Momentum and Technical Analysis Profile
Pharming Group N.V. (PHAR) has a momentum factor score of 78/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 74/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 48/100 reflects moderate short selling activity.
PHAR vs Competitors — Healthcare Sector Ranking and Peer Comparison
Comparing PHAR against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full PHAR vs S&P 500 (SPY) comparison to assess how Pharming Group N.V. stacks up against the broader market across all factor dimensions.
PHAR Next Earnings Date
No upcoming earnings date has been announced for Pharming Group N.V. (PHAR) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy PHAR? — Investment Thesis Summary
Pharming Group N.V. presents a balanced picture with arguments on both sides. Price momentum is positive at 78/100, suggesting the trend favors buyers.
In summary, Pharming Group N.V. (PHAR) earns a Hold rating with a composite score of 55.3/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on PHAR stock.
We'll email you when stocks you follow change their composite rating.
Institutional Research Dossier
Pharming Group N.V. (PHAR) Deep Dive Analysis
Published on March 24, 2026
Action RatingHold
Sections
Executive Summary
Pharming Group N.V. receives a Hold rating, driven by a mixed financial performance and a valuation that appears stretched relative to its profitability. While the company boasts a high gross margin and promising pipeline, its negative net income and free cash flow raise concerns about its near-term financial sustainability. The current valuation, particularly the high EV/EBITDA multiple, suggests that the market has already priced in significant future growth, leaving limited upside potential for investors at the current levels.
The company's focus on rare disease treatments offers a degree of insulation from broader market trends, but the inherent risks associated with drug development and regulatory approvals cannot be ignored. Pharming's success hinges on the continued growth of Ruconest sales and the successful commercialization of its pipeline products, particularly leniolisib. Until the company demonstrates consistent profitability and positive cash flow, a Hold rating is warranted, reflecting a balanced view of its potential and its challenges.
Business Strategy & Overview
Pharming Group N.V. operates as a biopharmaceutical company focused on developing and commercializing protein replacement therapies and precision medicines for rare diseases. Its primary revenue driver is Ruconest, a recombinant human C1 esterase inhibitor used to treat acute hereditary angioedema (HAE). The company's strategy revolves around expanding the market reach of Ruconest and advancing its pipeline of novel therapies targeting other rare conditions with significant unmet medical needs.
Beyond Ruconest, Pharming is actively developing leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) inhibitor for activated PI3K delta syndrome (APDS), and exploring alpha-glucosidase therapy for Pompe and Fabry diseases. These pipeline assets represent significant growth opportunities, but also introduce development and regulatory risks. The company's collaboration with Novartis and Orchard Therapeutics further diversifies its pipeline and leverages external expertise in specific therapeutic areas.
Pharming's commercial strategy involves direct sales and marketing efforts in key markets, including the United States and Europe. The company also relies on partnerships and distributors to reach other regions. This hybrid approach allows Pharming to maintain control over its core markets while expanding its global footprint through strategic alliances. The focus on rare diseases provides a degree of pricing power, but also necessitates significant investment in patient identification and disease awareness programs.
The company's strategic positioning within the rare disease space is both a strength and a weakness. The limited patient populations for these diseases reduce the potential market size compared to more prevalent conditions, but also limit competition and provide opportunities for orphan drug designations and accelerated regulatory pathways. Pharming's success depends on its ability to effectively navigate the complex regulatory landscape, secure reimbursement for its therapies, and build strong relationships with key opinion leaders and patient advocacy groups.
Execution Benchmarks audit
Gross Margin
Core pricing power
88.1%
Sector: 71.5%
+23% VS SCTR
Economic Moat Analysis
Pharming's economic moat is likely Narrow, primarily derived from intangible assets in the form of patents and regulatory exclusivity surrounding its lead product, Ruconest, and its pipeline candidates. The orphan drug designation for Ruconest provides a period of market exclusivity, limiting direct competition. However, this exclusivity is not perpetual, and the emergence of biosimilars or alternative therapies could erode Ruconest's market share over time.
The company's pipeline of novel therapies, such as leniolisib, represents a potential source of future moat expansion. If these therapies prove to be highly effective and receive regulatory approval, they could create new revenue streams and strengthen Pharming's competitive position. However, the inherent risks associated with drug development mean that there is no guarantee of success.
Switching costs for patients on Ruconest are likely moderate. While patients may be hesitant to switch from a therapy that is effectively managing their HAE symptoms, the availability of alternative treatments and the potential for improved efficacy or safety could incentivize switching. Therefore, Pharming must continue to innovate and demonstrate the value of its therapies to retain market share.
Pharming does not appear to possess significant cost advantages or benefit from efficient scale. The production of recombinant proteins is a complex and expensive process, and the company's relatively small size limits its ability to achieve economies of scale. Furthermore, the company's reliance on contract manufacturers for some of its production needs exposes it to supply chain risks and potentially higher costs.
Network effects are not a significant factor in Pharming's business model. While the company benefits from relationships with key opinion leaders and patient advocacy groups, these relationships do not create a self-reinforcing cycle of value creation that would constitute a network effect. Overall, Pharming's narrow moat is primarily based on intellectual property and regulatory exclusivity, which provide a limited degree of protection from competition.
Financial Health & Profitability
Pharming's financial health presents a mixed picture. While the company boasts a high gross margin (88.1% in FY2024), its net income and free cash flow have been volatile and recently negative. In FY2024, the company reported a net loss of $11.84 million and negative free cash flow of $1.45 million. This contrasts with the positive net income and free cash flow generated in FY2022 and FY2021, indicating a recent deterioration in financial performance.
The company's revenue has fluctuated significantly over the past few years. After experiencing growth in FY2021 and FY2022, revenue declined in FY2023 before rebounding in FY2024. This volatility reflects the inherent uncertainty associated with pharmaceutical sales and the impact of competition and pricing pressures. The dramatic increase in gross margin from FY2023 (176.6%) to FY2024 (88.1%) is unusual and warrants further investigation to understand the underlying drivers.
Pharming's balance sheet shows a moderate level of debt. As of the latest data, the company has $54.94 million in cash and $109.37 million in total debt, resulting in a debt-to-equity ratio of 49.00. While this level of leverage is not excessive, it does increase the company's financial risk, particularly in light of its negative net income and free cash flow. The sector average D/E is 30.00, making Pharming more leveraged than its peers.
Compared to the healthcare sector, Pharming's profitability metrics are mixed. While its gross margin is significantly higher than the sector average, its operating and net margins are lower. The company's negative ROE (-21.4%) is also a concern, although it is better than the sector average of -42.5%. The company's ability to generate sustainable profits and positive cash flow will be critical to its long-term financial health.
The negative free cash flow in recent years is a significant concern. While the company has sufficient cash on hand to cover its short-term obligations, continued negative cash flow could necessitate additional financing, which could dilute existing shareholders or increase the company's debt burden. The company needs to demonstrate a clear path to profitability and positive cash flow to alleviate these concerns.
Valuation Assessment
Pharming's valuation appears stretched based on its current financial performance. The company's P/E ratio is not applicable due to its negative net income. The EV/EBITDA multiple of 59.0x is significantly higher than the healthcare sector average of 6.4x, suggesting that the market has high expectations for future growth. This premium valuation may be justified if Pharming can successfully commercialize its pipeline products and achieve sustained profitability, but it also leaves limited margin for error.
Given the negative free cash flow, a traditional FCF yield analysis is not meaningful. However, the company's market capitalization of $1.07 billion suggests that investors are assigning significant value to its future growth potential. This valuation is predicated on the successful development and commercialization of its pipeline assets, as well as continued growth in Ruconest sales.
Compared to its historical valuation, Pharming's current valuation is higher than it has been in the past. The company's stock price has increased significantly in recent years, reflecting investor optimism about its growth prospects. However, this optimism may be overdone, given the company's recent financial performance and the inherent risks associated with drug development.
A discounted cash flow (DCF) analysis would be necessary to determine a more precise estimate of Pharming's intrinsic value. However, such an analysis would require making numerous assumptions about the company's future revenue growth, profitability, and cash flow generation. Given the uncertainty surrounding these assumptions, the results of a DCF analysis would be highly sensitive to the input parameters.
Overall, Pharming's valuation appears to be at the higher end of the spectrum, reflecting investor optimism about its growth prospects. While the company's focus on rare diseases and its promising pipeline offer potential for future value creation, the current valuation leaves limited upside potential for investors at the current levels. A more conservative valuation would be warranted until the company demonstrates consistent profitability and positive cash flow.
Risk & Uncertainty
Pharming faces several key risks that could impact its future performance. One of the most significant risks is the inherent uncertainty associated with drug development. The company's pipeline candidates, such as leniolisib, are subject to clinical trial failures, regulatory delays, and commercialization challenges. Any setbacks in the development of these therapies could negatively impact the company's revenue growth and profitability.
Competition is another significant risk. While Ruconest currently enjoys a strong market position, the emergence of biosimilars or alternative therapies could erode its market share. Furthermore, the company faces competition from other companies developing therapies for rare diseases. Increased competition could lead to pricing pressures and reduced profitability.
Regulatory risks are also a concern. The pharmaceutical industry is heavily regulated, and Pharming is subject to numerous regulations related to drug development, manufacturing, and marketing. Changes in these regulations could increase the company's costs and delay the approval of its therapies.
Pharming's reliance on a limited number of products and markets also poses a concentration risk. A significant portion of the company's revenue is derived from Ruconest sales in the United States and Europe. Any disruption to these sales, such as a loss of market share or a regulatory setback, could have a material adverse impact on the company's financial performance.
Finally, the company's debt burden increases its financial risk. While the company has sufficient cash on hand to cover its short-term obligations, continued negative cash flow could necessitate additional financing, which could dilute existing shareholders or increase the company's debt burden. The company's ability to generate sustainable profits and positive cash flow will be critical to managing its financial risk.
Bulls Say / Bears Say
The Bull Case
BULL VIEWPharming's focus on rare diseases provides a degree of insulation from broader market trends and offers opportunities for orphan drug designations and accelerated regulatory pathways.
BULL VIEWThe successful commercialization of leniolisib and other pipeline candidates could significantly boost revenue and profitability, justifying the current premium valuation.
The Bear Case
BEAR VIEWPharming's negative net income and free cash flow raise concerns about its near-term financial sustainability and its ability to fund its pipeline development.
BEAR VIEWThe high EV/EBITDA multiple suggests that the market has already priced in significant future growth, leaving limited upside potential for investors at the current levels.
About the Author
Marques Blank
Founder & Chief Investment Officer, Blank Capital
Marques brings 15 years of institutional finance and investing experience, having overseen financial planning for a $1.6B defense business unit. He developed the proprietary 6-factor quantitative model used to score PHAR and 4,400+ other equities.
Pharming Group N.V. exhibits a 188% valuation premium relative to institutional benchmarks. This represents a potential valuation overextension based on current multiples.
Return on Assets
Efficiency of asset utilization
-11.8%
Sector: -33.1%
Gross Margin
Pricing power and cost efficiency
88.1%
Sector: 71.5%
Operating Margin
Core business profitability
-2.9%
Sector: -66.1%
Net Margin
Bottom-line profitability
-4.0%
Sector: -58.7%
Factor Methodology
The Quality factor evaluates the persistence and magnitude of cash flows. Companies with scores >70 exhibit superior competitive moats and financial resilience through economic cycles.
